SCHEMBL6238926

SCHEMBL6238926

CC(C)C1(C)NC(=O)NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP3A4 P08684 1/20 0.32
GABRB3 P28472 1/20 0.32
OPRD1 P41143 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
LMNA P02545 1/20 0.32
CACNA1F O60840 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
HTR2A P28223 1/20 0.31
HRH1 P35367 1/20 0.31
SCN1A P35498 1/20 0.31
SCN4A P35499 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
CACNA1D Q01668 1/20 0.31
KCNH2 Q12809 1/20 0.31
CACNA1S Q13698 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10595759 0.76 LMNA (0.36) LMNA
SCHEMBL15974035 0.75 LMNA (0.38) ALDH1A1KDM4ECYP3A4GABRB3OPRD1
SCHEMBL4958726 0.74 ALDH1A1 (0.38) ALDH1A1KDM4ECYP3A4GABRB3OPRD1
SCHEMBL1101433 0.71 MEN1 (0.35) LMNAMAPTCYP2C9
SCHEMBL11173511 0.69 LMNA (0.40) ALDH1A1KDM4ECYP3A4GABRB3OPRD1
SCHEMBL12843938 0.69 HDAC1 (0.33) ALDH1A1MAPT
SCHEMBL4620887 0.68 LMNA (0.36) ALDH1A1KDM4ECYP3A4GABRB3OPRD1
SCHEMBL10534638 0.68 ADAMTS5 (0.31) ALDH1A1KDM4ECYP3A4GABRB3OPRD1
SCHEMBL2872028 0.68
SCHEMBL9539755 0.68 PDK2 (0.52) ALDH1A1KDM4ELMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0534774-A1 5,5-Dialkyl hydantoins for promoted acid gas scrubbing processes EXXON CHEMICAL PATENTS INC. (US) 1993-03-31 EP claimed
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-09-24 US disclosed
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE LYCERA CORPORATION 2018-04-26 US disclosed
US-8394960-B2 Thiazole carboxamide derivatives and their use to treat cancer MERCK SHARP & DOHME CORP. (US) 2013-03-12 US disclosed
WO-2013001498-A1 AMIDOALKYLPIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES ADAMED SP. Z O.O. (PL) 2013-01-03 WO disclosed
US-20110044940-A1 Thiazole Carboxamide Derivatives and Their Use to Treat Cancer SCHERING CORPORATION 2011-02-24 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20080221092-A1 Heterobicyclic metalloprotease inhibitors BLUHM HARALD 2008-09-11 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-4883914-A Benzenesulfonyl carboxamide compounds useful as herbicidal agents AMERICAN CYANAMID COMPANY (US) 1989-11-28 US disclosed
EP-0303863-A2 Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents AMERICAN CYANAMID COMPANY (US) 1989-02-22 EP disclosed
US-4668273-A Quaternary ammonium salts of diepoxides and diamines, their preparation and use CIBA-GEIGY CORPORATION (US) 1987-05-26 US disclosed
EP-0026157-B1 QUATERNARY AMMONIUM SALTS FROM DIEPOXYDES AND DIAMINES, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1984-06-13 EP disclosed
US-4332953-A FOR PREPARING URETHANE FOAMS AND ELASTOMERS BASF WYANDOTTE CORPORATION (US) 1982-06-01 US disclosed
US-4331809-A INTERMEDIATES FOR PREPARING POLYURETHANE FOAMS AND ELASTOMERS BASF WYANDOTTE CORPORATION (US) 1982-05-25 US disclosed
US-4331810-A Carbamylbiuret-modified polyisocyanates BASF WYANDOTTE CORPORATION (US) 1982-05-25 US disclosed
US-4330636-A Carbamylbiuret-modified polyisocyanates BASF WYANDOTTE CORPORATION (US) 1982-05-18 US disclosed
US-4271087-A WHICH CAN ALSO CONTAIN GUANIDINE LINKAGES AND THIOUREA LINKAGES BASF WYANDOTTE CORPORATION (US) 1981-06-02 US disclosed
EP-0026157-A2 Quaternary ammonium salts from diepoxydes and diamines, their preparation and their use CIBA-GEIGY AG (CH) 1981-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE RORB, RORA, RORC ALDH1A1 163/4885KDM4E 2051/4885CYP3A4 502/4885
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885KDM4E 2058/4885CYP3A4 708/4885
US-20110044940-A1 Thiazole Carboxamide Derivatives and Their Use to Treat Cancer LCK, TEC, MTOR ALDH1A1 2981/4885KDM4E 1767/4885CYP3A4 2610/4885
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORB, RORA, RORC ALDH1A1 201/4885KDM4E 2334/4885CYP3A4 444/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885KDM4E 2058/4885CYP3A4 708/4885
US-20080221092-A1 Heterobicyclic metalloprotease inhibitors MMP13, MMP3, TIMP3 ALDH1A1 1875/4885KDM4E 2290/4885CYP3A4 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.